CTLA4 Screening Services
Cytotoxic T-lymphocyte associated protein 4, or CTLA4, is a receptor which has emerged as a validated target for immunotherapies. CTLA4 is expressed on the surface of activated T cells and works to downregulate the immune system's responses. CTLA4 competes with CD28 for the ability to bind to B7 ligands, B7-1 and B7-2. When B7 proteins bind to CD28, pro-survival signals are transmitted to T cells. However, when CTLA4 binds to B7 proteins instead, T cell activation is inhibited and inflammatory immune responses are prevented.
The first checkpoint inhibitor approved by the Food and Drug Administration (FDA) in March of 2011 was the anti-CTLA4 antagonistic antibody, ipilimumab (YervoyTM, Bristol-Myers Squibb). Its approval was a turning point in the history of melanoma and cancer treatment, as it was the first ever therapy to demonstrate improved overall survival in a randomized phase III trial for metastatic melanoma . The age of immune oncology had officially begun.
BPS Bioscience offers CLTA4 screening and profiling services to identify inhibitors of CTLA4:B7-1 and CTLA4:B7-2 interaction in addition to CTLA4:B7-1 and CTLA4:B7-2 inhibitor screening assay kits. Through use of these services and kits, one can very quickly identify small molecules and biologics that interfere with CTLA4:B7-1/B7-2 interaction before proceeding with more sophisticated screens.
Using BPS’s CTLA screening services, we can help accelerate your research and drug discovery programs. Trust us to provide you with high quality data with fast turnaround time. Our team of experts along with our broad services portfolio makes it easy to:
- Screen for inhibitors/targets using our CTLA4 assays
- Select from IC50 determination and single point concentrations
- Receive data within days of compound submission
- Perform follow-up studies using the same soluble receptors manufactured in-house
- Get questions answered or project guidance in a time-efficient manner
Contact BPS today to find out more about how we can assist you in your CTLA4 related research.
- Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al.Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-723.
Not quite what you're looking for? We also offer custom assays for several other immunotherapy targets. Our Custom Assay Development Services allow for flexibility to meet your specific research needs.
Want to Streamline Your Project?
Looking for more?